![Sample our Behavioral Sciences journals, sign in here to start your access, latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/110801/TOC-Subject-Sample-2021-Behavioral-Sciences.jpg"})
Abstract
Kay Davies is the Dr Lee's Professor of Anatomy in the Department of Physiology, Anatomy and Genetics, and Director of the MRC Functional Genomics Unit at the University of Oxford, UK. Her research interests lie in the molecular analysis and development of treatment for human genetic disease, particularly, Duchenne muscular dystrophy (DMD) and the application of genomics for the analysis of neurological disorders and gene–environment interactions. She is co-founder of a company, Summit Therapeutics, which aims to deliver utrophin modulation to the clinic for the therapy of DMD, which currently has a drug in Phase 1 trials. She has published more than 400 papers and won numerous awards for her work. She is a founding fellow of the UK Academy of Medical Sciences and was elected a Fellow of the Royal Society in 2003. She has been a Governor of the Wellcome Trust since 2008 and became Deputy Chairman in October, 2013. She was made Dame Commander of the British Empire for services to science in 2008.
Disclaimer
The opinions expressed in this interview are those of the interviewee and do not necessarily reflect the views of Future Medicine Ltd.
Financial & competing interests disclosure
Kay E Davies is a shareholder of Summit Therapeutics and on the Scientific Advisory Board of Summit Therapeutics and Prosensa. The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
No writing assistance was utilized in the production of this manuscript.